SUBSCRIBE
SUBSCRIBE
News   Drug Development

Major Study Clears GlaxoSmithKline’s Avandia of Heart Risk

June 8, 2009 | 
1 min read
Reuters -- GlaxoSmithKline's controversial diabetes drug Avandia doesn't increase overall heart risks, according to final results of a large clinical study sponsored by the world's second largest drugmaker.
Clinical research Postmarket research
GlaxoSmithKline
MORE ON THIS TOPIC
Creative collage image young man builder architect engineer occupation lungs healthcare illness disease drawing background.
Lung cancer
Cullinan, Taiho’s NSCLC Hopeful Shows ‘Strong Activity,’ Clearing Road to FDA
September 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
 · 
1 min read
 · 
Jef Akst
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage art of a hand touching a cat. Modern and creative design with surreal style. Perfect for use in posters, editorial design, social media, digital art, and contemporary art projects
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac